↓ Skip to main content

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies

Overview of attention for article published in Investigational New Drugs, September 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

patent
2 patents

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
26 Mendeley